A *nadA* mutation confers nicotinic acid auxotrophy in pro-carcinogenic intestinal *Escherichia coli* NC101

Lacey R. Lopez,^a Cassandra J. Barlogio,^{a*} Christopher A. Broberg,^{a*} Jeremy Wang,^b Janelle C. Arthur,^{a,c,d#}

^aDepartment of Microbiology and Immunology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

^bDepartment of Genetics, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

^cCenter for Gastrointestinal Biology and Disease, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

^dLineberger Comprehensive Cancer Center, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

Running title: Eliminating *E. coli* micronutrient constraints

*Present address: Locus Biosciences, Inc., Durham, North Carolina, United States of America.

•Present address: Department of Chemistry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America

#Address correspondence to Janelle C. Arthur, Janelle_arthur@med.unc.edu

Abstract word count (max 250): 204 words

Importance word count (*max 120*): 120 words

Main text word count (*max 5000*): 3999 words

Abstract

Inflammatory bowel diseases and inflammation-associated colorectal cancer are linked to blooms of adherent-invasive *Escherichia coli* (AIEC) in the intestinal microbiota. AIEC are functionally defined by their ability to adhere/invade epithelial cells and survive/replicate within macrophages. Changes in micronutrient availability can alter AIEC physiology and interactions with host cells. Thus, culturing AIEC for mechanistic investigations often involves precise nutrient formulation. We observed that the pro-inflammatory and pro-carcinogenic AIEC strain NC101 failed to grow in minimal media (MM). We hypothesized that NC101 was unable to synthesize a vital micronutrient normally found in the host gut. Through nutrient supplementation studies, we identified that NC101 is a nicotinic acid (NA) auxotroph. NA auxotrophy was not observed in the other non-toxigenic *E. coli* or AIEC strains we tested. Sequencing revealed NC101 has a missense mutation in *nadA*, a gene encoding quinolinate synthase A that is important for *de novo* NAD biosynthesis. Correcting the identified *nadA* point mutation restored NC101 prototrophy without impacting AIEC function, including motility and AIEC-defining survival in macrophages. Our findings, along with the generation of a prototrophic NC101 strain, will greatly enhance the ability to perform *in vitro* functional studies that are needed for mechanistic investigations on the role of intestinal *E. coli* in digestive disease.

Importance

Inflammatory bowel diseases (IBD) and colorectal cancer (CRC) are significant global health concerns that are influenced by gut resident microbes, like adherent-invasive *Escherichia coli* (AIEC). Nutrient availability influences specialized metabolite production, AIEC-defining functional attributes, and AIEC:host interactions. NC101 is a pro-inflammatory and pro-carcinogenic AIEC strain commonly used for studies on IBD and CRC. We identified that NC101 growth *in vitro* requires a micronutrient found in the host gut. By correcting an identified mutation, we generated an NC101 strain that no longer has micronutrient restrictions. Our findings will facilitate future research that necessitates precise nutrient manipulation, enhancing AIEC functional studies and investigations on other auxotrophic intestinal microbiota members. Broadly, this will improve the study of bacterial:host interactions impacting health and disease.

Introduction

Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are a major global health concern that affects over 3 million adults in the United States alone (1, 2). IBD is a chronic and multifactorial disease that is driven by aberrant immune responses to commensal microbes, genetic susceptibility, and environmental factors (3). IBD patients experience painful, chronic, and relapsing intestinal inflammation that can lead to life-threatening complications, including intestinal fibrosis and colorectal cancer (CRC) (4, 5). Experimental models have demonstrated that IBD and CRC can be driven by the intestinal microbiota and that specific microbes, such as *Escherichia coli*, are associated with human disease (6, 7). IBD and CRC have

no single etiology and no cure (8, 9). Therefore, understanding the function of disease-associated gut microbes may uncover novel therapeutic options for intestinal diseases, like IBD and CRC.

Intestinal microbes influence the onset and progression of IBD and CRC via metabolite production and modulation of mucosal immunity (10–14). *E. coli* are common inhabitants of the intestinal microbiota (15, 16). Strain level differences can alter the pro-inflammatory or pro-carcinogenic potential of *E. coli*, partly through changes in small molecule production (12–14, 17, 18). A pathovar of *E. coli*, termed adherent-invasive *E. coli* (AIEC), are enriched in the gut microbiota of human IBD and CRC patients (19). AIEC exacerbate experimental colitis and promote CRC in a variety of murine models (17, 18, 20–24). There is no genetic definition for AIEC (14, 19, 25). Instead, AIEC are classically defined by their ability to adhere/invade epithelial cells and survive/replicate within macrophages (19, 26). Environmental conditions, including nutrient availability and intestinal inflammation, can alter AIEC behavior and impact intestinal colonization and disease (14, 17, 27–30). Therefore, the ability to precisely manipulate AIEC growth conditions is essential for *in vitro* studies investigating AIEC behavior and production of pro-inflammatory and pro-carcinogenic molecules.

E. coli NC101 is a well-known AIEC strain utilized by numerous investigators to study how intestinal *E. coli* adapt to and influence the host during IBD and CRC (14, 17, 18, 24, 31–33). NC101 was originally isolated from a specific pathogen free wild-type mouse at North Carolina State University (34). Colonizing wild-type mice with NC101 does not induce intestinal pathology, even during monoassociation studies using gnotobiotic animals (17). However, despite a lack of traditional toxins and virulence factors, NC101 induces antigen-driven intestinal inflammation in genetically-susceptible IBD mouse models (e.g. interleukin 10 deficient mice) (34). Thus, NC101 is considered a pathobiont and a highly relevant model organism for defining

how susceptible individuals may mount inappropriate immune responses to seemingly innocuous intestinal *E. coli*.

NC101 adapts to the inflamed intestinal milieu by modulating expression of its gene repertoire (35, 36). Nutrient availability alters AIEC physiology, persistence in the microbiota, and production of pro-inflammatory and pro-carcinogenic mediators (14, 17, 27–30). Monoassociation studies with gnotobiotic mice have led to the discovery of several AIEC-derived host-influencing molecules (i.e. specialized metabolites) that drive inflammation and tumorigenesis, including yersiniabactin and colibactin (17–19). Like many specialized metabolites, yersiniabactin and colibactin are produced via biosynthetic gene clusters that can be activated by changes in micronutrient availability, notably iron (37, 38). The nature of AIEC-derived specialized metabolites makes them difficult to isolate and study in functional assays. Therefore, the repertoire of AIEC-derived metabolites and their impact on the host has been largely unexplored.

Variations in micronutrient availability can impact the virulence and physiology of AIEC (27, 28, 39). Therefore, culturing AIEC for mechanistic studies necessitates using a simplified base media that allows for precise nutrient manipulation. During our studies, we observed that modified M9 minimal media (MM) does not sustain NC101 growth *in vitro*. We hypothesized that NC101 was an auxotroph. Through nutrient supplementation studies, we discovered that NC101 requires nicotinic acid (NA, niacin, Vitamin B3) for growth. NA auxotrophy was not observed in other non-toxigenic laboratory *E. coli* strains (K12 or 25922), AIEC, or non-AIEC human intestinal strains (40). Genetic evaluation revealed that NC101 has a missense mutation in the NAD biosynthesis gene (*nadA*) that encodes for quinolinate synthase A. Importantly, we generated a prototrophic NC101 revertant strain that eliminated *E. coli* micronutrient restraints.

Correcting NC101 auxotrophy had negligible impact on NC101 function, including motility and AIEC-defining survival in macrophages.

NC101 micronutrient constraints have limited our ability to perform *in vitro* functional studies, which often require careful nutrient manipulation. Overall, our findings will enable precise nutrient manipulation for mechanistic studies on auxotrophic microbiota members, like AIEC, *Shigella spp.*, or Uropathogenic *E. coli* (41–44). Importantly, our work will facilitate *in vitro* functional assays and small molecule purification efforts with the pro-inflammatory and pro-carcinogenic AIEC strain NC101. Furthermore, these studies will broadly improve our understanding of the microbiota in intestinal diseases like IBD and CRC.

Results

The pro-carcinogenic adherent-invasive *E. coli* strain NC101 requires nicotinic acid to sustain growth

During *in vitro* studies to evaluate AIEC function in long-term culture (24+ hr), we attempted to passage NC101 in modified M9 minimal media (MM) that includes glycerol and casamino acids. NC101 can successfully be subcultured from Luria-Bertani (LB) agar or broth, a rich medium, to MM (17, 28). However, NC101 failed to grow when subcultured from MM to MM (**Fig. 1A-C**). We hypothesized that NC101 was an auxotroph, unable to synthesize a key nutrient found in the murine gut. *Shigella spp.*, a transient gut pathogen and close relative of *E. coli*, are generally nicotinic acid (NA, Niacin, Vitamin B3) auxotrophs (41, 43–45). Thus, we specifically tested

whether vitamin supplementation could restore NC101 growth in MM. Supplementing MM with a complex Vitamin Mix (VM) restored NC101 growth at 8hr and 24hr (**Fig. 1A-B**).

To identify which vitamin(s) in the VM were essential for NC101 growth, we supplemented MM with individual or combinations of VM components and assessed NC101 growth. Tryptophan supplementation was also tested, as tryptophan metabolism can be influenced by host-microbe interactions in the gut (46). Only MM containing NA, alone or in combination, sustained NC101 growth in MM at 8hr and 24hr (**Fig. 1B**). Further, NA alone restored normal NC101 growth kinetics in MM and significantly enhanced growth at 24hr (**Fig. 1C**). NC101 grew when subcultured from MM to LB, indicating NC101 does not have a global growth defect (**Fig. 1A-C**). Together, these data suggest NC101 is an NA auxotroph.

NA auxotrophy is not a defining feature of non-toxigenic *E. coli*

Resident non-toxigenic *E. coli* are common among the intestinal microbiota and many are considered commensal strains (15, 16). Yet, other *E. coli* (e.g. AIEC) are associated with chronic intestinal inflammation and may be referred to as pathobionts (15, 19). We questioned whether NA auxotrophy was shared across clinically derived non-toxigenic *E. coli*. In addition to evaluating model *E. coli* strains (K12 and 25922), we evaluated clinical specimens isolated from the intestinal mucosa of IBD or non-IBD patients (*E. coli* LF82, 42ET-1, 568-3, HM670, 37RT-2, 532-9, and 39ES-1) (40, 47, 48) (**Table 1**). These clinical isolates have been characterized in the lab from which they originated for AIEC status, and at least partial genome sequences are available for all strains (40). To determine the extent of NA-dependency among these strains, we passaged isolates in MM with and without NA and assessed growth by measuring optical density (OD₆₀₀) at 2hr, 4hr, 8hr, and 24hr (**Fig. 2A**). We again observed that NC101 had a growth defect

in MM, detectable at 2hr and continuing through 24hr (**Fig. 2A**). However, all examined laboratory strains and clinical isolates grew in MM with and without NA. (**Fig 2A**). Therefore, NA auxotrophy does not appear to be a defining characteristic shared by non-toxigenic resident intestinal *E. coli*.

LF82 is a well-known human-derived AIEC strain that can grow in MM without NA (48) (**Fig. 2A-B**). We directly compared the growth kinetics of NC101 and LF82 in MM with and without NA (**Fig. 2B**). While early growth of LF82 in MM was minimally enhanced by NA, this difference was indistinguishable by 6hr (**Fig. 2B**). Thus, the prototypic AIEC strain LF82 does not exhibit NA auxotrophy. Combined with our findings in Fig. 2A, we conclude that NA auxotrophy is not an AIEC-defining feature.

NC101 has a defect in the *de novo* NAD biosynthesis pathway

NA is a precursor for NAD biosynthesis (41). NAD is an electron carrier and an essential cofactor for bacterial metabolism (41). In *E. coli* and related bacteria, NAD can be synthesized *de novo* from L-aspartate (L-asp) through the generation of quinolinic acid (quinolinate, Qa). In this process, Quinolinate synthase A and B (encoded by *nadA* and *nadB*, respectively) catalyze the oxidation of L-asp to iminoaspartate and condensation with dihydroxyacetone phosphate to generate quinolinate (41). Quinolinate is converted to nicotinic mononucleotide (NaMN) by a *nadC* encoded enzyme and ultimately NAD via enzymes encoded by *nadD* and *nadE* (41). NAD biosynthesis can also occur through salvage pathways that utilize vitamin precursors like NA or nicotinamide (Nm) (41, 43, 49) (**Fig. 3A**).

Since NA restored the growth of NC101, we predicted that NC101 had a defect within the NAD biosynthesis pathway. To determine whether this was the case, we assessed NC101 growth in

MM supplemented with key NAD biosynthesis intermediates: L-asp, Qa, Nm, NA, and NAD. L-asp failed to consistently sustain NC101 growth in MM. Conversely, Qa sustained NC101 growth in MM and Nm, NA, and NAD significantly restored growth across all timepoints (**Fig. 3B**). Growth curves revealed the kinetics of enhanced NC101 growth in the presence of the restorative NAD biosynthesis intermediates: Qa, Nm, Na, and NAD (**Fig. 3C**). When examining the NAD biosynthesis pathway, this indicated that NC101 likely had a defect in the NAD biosynthesis genes *nadA* or *nadB* (**Fig. 3A**)

NA auxotrophy in NC101 is linked to a mutation in NAD biosynthesis gene *nadA*

After our growth supplementation assays revealed a likely defect in *nadA* or *nadB*, we sought to identify the genetic factor(s) responsible for NA auxotrophy in NC101. We performed whole genome sequencing on wild-type (WT) NC101 and compared the sequence to prototrophic *E. coli*, LF82 and K12. Sequencing revealed that WT NC101 has a missense mutation in *nadA* (T263G) that was associated with auxotrophy (**Fig. 4A**).

To further validate the genetic determinants of NC101 NA auxotrophy, we generated a prototrophic strain by passaging WT NC101 on MM agar plates in the absence of NA (42). Sequencing of a selected spontaneous prototrophic revertant, termed NA_{Derivative} or NA_D NC101, revealed that NA_D NC101 had a single nucleotide substitution in *nadA* (G263T, compared to WT) that matched the prototrophic *E. coli* strains LF82 and K12 (**Fig. 4A**). It is important to note that NA_D NC101 also had a silent mutation in an intergenic region that was absent from WT NC101, but we predict this mutation had no impact on NA_D NC101 prototrophy (Accession #SAMN16810912) (**Table 2**). To support that NA auxotrophy is due to the observed *nadA* mutation, our whole genome sequencing revealed that two other NC101 spontaneous

prototrophic revertants had missense mutations in *nadA* – one of which shared the same *nadA* (G263T, compared to WT) nucleotide substitution as NA_D NC101 (Accession #SAMN16810913 and #SAMN16810914) (**Table 2**).

To confirm that the NA_D revertant restored prototrophy, we grew WT NC101 and NA_D in MM with and without NA. NA_D grew significantly better in MM versus WT NC101 at 24hr (**Fig. 4B**). Growth of NA_D in the absence of NA was the equivalent to WT grown with added NA, as noted by overlapping growth curves (**Fig. 4B**). The addition of NA did not significantly enhance NA_D growth in MM, suggesting NA auxotrophy was successfully eliminated in this strain (**Fig. 4B**). These findings are consistent with the literature, which indicates NadA is important for NAD biosynthesis and mutations in *nadA* can drive NA auxotrophy in *E. coli*, *Shigella spp.*, and *Salmonella spp.* (41, 43, 44, 50). Therefore, our data support that NC101 NA auxotrophy is due to a mutation in *nadA*.

Correcting NA auxotrophy in NC101 has negligible impact on bacterial motility or AIEC-associated survival in macrophages

To determine if correcting NA auxotrophy impacted AIEC physiology and interactions with mammalian cells, we assessed WT and NA_D NC101 for motility and survival in macrophages. Motility is not an AIEC-defining feature, but hypermotility has recently been linked to changes in AIEC:host interactions (19, 51). Due to the WT NA auxotrophy, motility was only assessed on MM agar plates supplemented with NA. There was no significant difference in motility between WT and NA_D NC101 in the presence of NA (**Fig. 5A**). However, the motility of both WT and NA_D NC101 differed significantly from the non-motile control mutant, NC101 *ΔfliC* (flagellar filament structural protein) (51) (**Fig. 5A**).

A key feature of AIEC is enhanced survival in macrophages, a characteristic linked to their pro-inflammatory activities (26, 52). To evaluate whether the identified *nadA* mutation impacted AIEC-defining survival in macrophages, WT and NA_D NC101 were subcultured in MM with and without NA and used to infect macrophage cell cultures, which were also maintained in the presence or absence of NA. Despite the expected differences in culture densities between WT and NA_D strains upon subculturing in MM without NA (**Fig. 1C**), we could obtain a sufficient amount of WT NC101 to infect with an equivalent multiplicity of infection for all experiments. Baseline macrophage cell culture media contains an excess of NA, so as expected, there were not WT NC101 survival defects in the infection assay. Importantly, we found there were no significant differences in AIEC intramacrophage uptake (1hr) or survival (24hr) between WT and NA_D NC101 in the presence or absence of NA supplementation (**Fig 5B-D**). Therefore, eliminating NA auxotrophy in NA_D NC101 had negligible impact on these AIEC-associated functions.

Discussion

E. coli are common members of the mammalian microbiota (15, 16). Many *E. coli* isolates are prototrophic (41). However, a study identified that NA auxotrophy was common among the B2 phylotype of *E. coli* strains that are usual intestinal inhabitants (41). Herein, we illustrate that the AIEC strain NC101 (phylotype B2) is an NA auxotroph due to a missense mutation in NAD biosynthesis gene *nadA*. These findings are significant, as NC101 is an established AIEC often used for studies on IBD and CRC; yet, NA auxotrophy in NC101 has not been defined (14, 17, 18, 24, 31–33).

It is unclear why NC101 possesses NA auxotrophy versus the human-derived resident *E. coli* we examined (**Fig. 2**). Perhaps some feature of the murine intestinal environment promoted this NC101 characteristic. Genome reduction or loss-of-function mutations may facilitate adaptation to the intestinal microenvironment, as the decrease in biosynthetic cost of compounds likely provides an advantage when key nutrients are consistently present within an environment (53, 54). It is possible that loss of NAD biosynthesis gene function represents a way in which AIEC NC101 adapted to survive within the murine host. For example, an abundance of NA in the murine diet may have permitted murine-adapted NC101 with a mutation in *nadA* to persist in the gut, despite NA auxotrophy. It is also possible that among the many stochastic mutations experienced by *E. coli* strains, this *nadA* mutation simply conferred no benefit or detriment, allowing it to persist as a resident microbe of the murine gastrointestinal tract.

Besides reducing biosynthetic cost, Na/NAD play a key role in virulence and signaling across various microbial species, including *E. coli*, *Shigella spp.*, *Candida glabrata*, *Bordetella pertussis*, and *Legionella pneumophila* (41–44, 55–58). In *E. coli*, NA can regulate the EvgA/EvgS two-component regulatory system that drives multidrug resistance and acid tolerance (56, 59). While in *Shigella spp.*, a pathogen but close relative of nonpathogenic *E. coli*, loss of functional NAD biosynthesis genes (often *nadA* and/or *nadB*) reduces *Shigella* virulence and alters interactions with host cells (44, 55). However, our results demonstrate that NA auxotrophy does not impact a pro-inflammatory and key defining feature of AIEC, survival in macrophages.

The intestinal microbiota comprises a large/diverse collection of host-associated microbes, microbial genes, and products (6). Our lab and others have been interested in pro-inflammatory and pro-carcinogenic molecules derived from intestinal bacteria, namely yersiniabactin and

colibactin (17, 18). Many host-influencing microbial-derived molecules, often termed specialized metabolites, are produced by sophisticated multi-enzymatic machinery encoded by bacterial biosynthetic gene clusters. By nature, many of these specialized metabolites are difficult to isolate and purify in sufficient amounts for functional analysis. However, their production can often be activated by nutrient deficiency (12, 39, 60). Therefore, studies on specialized metabolites and their interactions with host cells often requires precise nutrient manipulation to study *in vitro*. To optimize the production of these unique bioactive molecules and reduce non-essential media components that complicate purification, we have identified the minimal media components necessary to grow the model AIEC NC101 and generated an NC101 strain no longer restricted by NA auxotrophy. This strain, NC101 NA_D, can easily be cultured in MM for functional studies or used to purify AIEC specialized metabolites. Ultimately this strain, NA_D NC101, can now serve as a research tool to investigate how precise nutrient manipulation impacts AIEC behavior under minimal media conditions.

In summary, our work in defining and correcting the NA auxotrophy in AIEC NC101 will 1) enable precise nutrient manipulation for *in vitro* studies on AIEC as they relate to IBD and CRC, 2) inform culture-based methods to evaluate the function of other auxotrophic gut microbiota members and their metabolites, and 3) facilitate small molecule isolation and purification from the pro-inflammatory and pro-carcinogenic strain NC101. Long-term, we expect our findings will contribute to the identification of microbiota-derived prognostic and therapeutic targets for human digestive diseases.

Materials and Methods

Bacterial strains: Descriptions of *E. coli* strains used in this study are listed in **Table 1**. NC101

$\Delta fliC$ was generated using the λ -red recombinase method, as previously described (17, 61).

Primers used for $\Delta fliC$ generation are listed in **Table 3**.

Media composition

M9 minimal-defined media (MM) – 5X M9 salts: 64g $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$, 15g anhydrous KH_2PO_4 , 2.5g NaCl , and 5g NH_4Cl brought to 1L in diH_2O (62). **Complete MM:** 0.1mM CaCl_2 , 1X M9 salts, 2mM MgSO_4 , 0.4% glycerol, and 0.2% casamino acids (CAA, Sigma #2240) brought to 1L in diH_2O . Where indicated, the following were added at these final concentrations: nicotinic acid (NA, Sigma #N4126), 50 $\mu\text{g/L}$; L-aspartate (L-asp), 200mg/L; nicotinamide (Nm), 50 $\mu\text{g/L}$; and NAD, 1 $\mu\text{g/L}$.

Vitamin mix (VM), 100X stock: 2mg folic acid, 10mg pyridoxine hydrochloride, 5mg riboflavin, 2mg biotin, 5mg thiamine, 5mg nicotinic acid, 5mg calcium pantothenate, 0.1mg vitamin B12, 5mg p-aminobenzoic acid, 5mg thiocctic acid, and 900mg monopotassium phosphate brought to 1L in diH_2O and aliquoted into 10mL stocks. One 10mL stock was used per liter of media. Formulation is from ATCC and is based on Wolfe's Vitamin solution (ATCC® MD-VS™).

Overnight cultures: Bacterial strains were preserved at -80°C and grown overnight at 37°C on Luria Bertani (LB, Fisher Sc. #BP9722-2) agar plates. Isolated colonies were transferred to MM and grown overnight ($>15\text{hrs}$) at 37°C with shaking at 220 rpm.

Growth assays: Overnight cultures were centrifuged and washed three times with 1X phosphate buffered saline (PBS), to remove any trace compounds contained in the culture. Cells were re-suspended and normalized by optical density (OD₆₀₀) in test media. Cultures were grown at 37°C with shaking at 220 rpm. For passaging assays, OD₆₀₀ was recorded at the indicated timepoints (2hr, 4hr, 8hr or 24hr). For growth curves, OD₆₀₀ was recorded every 45min for 6hr and a final timepoint was recorded at 24hr.

Spontaneous prototrophic revertant generation: WT NC101 was grown overnight in MM + NA, 5mL of the culture was centrifuged, and the supernatant discarded. The cell pellet was washed twice with 1X PBS and resuspended in 500μL 1X PBS. A 100 μl spot was spread onto each of five MM agar plates without NA. Plates were incubated at 37°C and monitored for growth of revertant colonies (42). Colonies were grown on MM without NA to confirm prototrophy and isolates were preserved at -80°C. Whole genome sequencing was performed to determine the location and nature of the mutation(s) leading to reversion. The revertant used in these studies was termed NC101 NA_{Derivative} (NA_D).

NC101 genome assembly: A complete NC101 genome was assembled from nanopore sequence using Minimap2 and Miniasm (63). The assembly was circularized and polished four times with Racon (64) followed by once with Medaka (Oxford Nanopore Technologies, <https://github.com/nanoporetech/medaka>). Matched Illumina sequence data was used to polish the resulting assembly using FMLRC (65) with parameters “-k 21 -K 30 -m 3 -f 0.05 -B 10”. The final polished genome was rotated and linearized such that it starts at the origin of replication.

Whole genome sequencing: Three spontaneous prototrophic revertants, including NA_D, were sent for whole genome sequencing. Samples were sent to the Microbial Genome Sequencing Center (MiGS), formerly at the University of Pittsburgh, for genomic DNA extraction and Illumina 2x150 paired end sequencing on the NextSeq 550 platform. Sequencing reads were mapped to our closed NC101 genome using CLC Genomic Workbench7.5.1 with average coverage of 85x for JA0257, 62x for JA0265, and 75x for JA0266. Sequences for LF82 (NC_011993.1) and K12 (NC_000913.3) were obtained from the National Center for Biotechnology Information (NCBI) and all alignments were analyzed via Geneious Prime version 2020.1.2. Assembled sequences from this study were deposited in NCBI and repository information is listed in **Table 2**.

Motility: Isolates were grown overnight, as described above. A 1μL spot was used to inoculate the center of MM soft agar plates (MM + 0.25% agar) with NA. Plates were incubated at 37°C for 8hr and the diameters of motility swarms were measured.

Macrophage survival assays: Bacterial intramacrophage survival was measured using the standard gentamicin protection assay for AIEC bacteria (26, 28). The J774A.1 murine macrophage-like cell line was used as a model and maintained according to ATCC standards in DMEM + 10% heat-inactivated FBS (DMEM, Gibco #11995-065). J774A.1 cells were seeded at 2x10⁵ cells/mL in 1mL media into 24-well plates (Falcon #353047) and grown overnight. The next day, bacterial overnight cultures were subcultured in MM with and without NA for 3hr. Before infection, J774A.1 monolayers were washed twice with 1X PBS. Then, subcultured bacteria were added at a multiplicity of infection (MOI) = 10 in cell culture media with and

without NA. Plates were spun at $180 \times g$ for 5min. Prepared bacterial cultures were serial diluted and plated on LB agar plates to validate infection dose.

After a 30min incubation at 37°C with 5% CO_2 , infected cultures were washed twice with 1X PBS and gentamicin-laden media was added ($100\mu\text{g/mL}$ gentamicin for 1hr timepoint and $20\mu\text{g/mL}$ for 24hr in DMEM + 10% FBS with and without NA). At 1hr and 24hr, cells were washed twice with 1X PBS and $500\mu\text{L}$ of 1% Triton X-100 in dH_2O was added to each well for 5min. Samples were mixed, serial diluted, and plated on LB agar plates to determine viable colony forming units (CFU). Percent intracellular bacteria = $[(\text{CFU/mL at 24hr})/(\text{CFU/mL at 1hr})] \times 100$.

Statistics: Statistical analysis was performed using Prism version 9.0.0 (GraphPad software San Diego, CA). A Welch's t test was used when two experimental groups were compared and a one-way ANOVA with Dunnett's T3 multiple comparisons test was used when 3 or more experimental groups were compared. Differences with a p-value less than 0.05 were considered significant. All experiments included at least 3 biological replicates with 1-2 technical replicates each, per timepoint.

Data availability: Assembled sequences from our whole genome sequencing, above, were deposited in NCBI and repository information is listed in **Table 2**.

Acknowledgments

We thank the following colleagues for kindly gifting *E. coli* strains: R. Balfour Sartor, University of North Carolina (UNC) at Chapel Hill (*E. coli* NC101, LF82, and K12 MG1655); Kenneth W. Simpson, Cornell University (*E. coli* 42ET-1, 568-3, 37RT-2, 532-9, and 39ES-1); Leslie M. Hicks, UNC at Chapel Hill (*E. coli* 25922); Barry J. Campbell, University of Liverpool (*E. coli* HM670); Melissa Ellermann, University of South Carolina at Columbia (NC101 Δ *fliC*). We thank Dr. Kimberly Walker for critical reading of the manuscript. NC101 genome assembly was supported by Jeremy Wang NIH K01DK119582 (JW). The remaining body of this work was supported by funding from NIH R01DK124617 (JCA), pilot funding from NIH P30DK034987 (subcontract JCA), and a UNC Lineberger Comprehensive Cancer Center Innovation Award (JCA).

References

1. Dahlhamer JM, Zammitti EP, Ward BW, Wheaton AG, Croft JB. 2016. Prevalence of inflammatory bowel disease among adults aged ≥ 18 years — United States, 2015. MMWR Morb Mortal Wkly Rep 65:1166–1169.
2. Kaplan GG. 2015. The global burden of IBD: From 2015 to 2025. Nat Rev Gastroenterol Hepatol 12:720–727.
3. Khor B, Gardet A, Xavier RJ. 2011. Genetics and pathogenesis of inflammatory bowel disease. Nature 474:307–317.
4. Rieder F, Brenmoehl J, Leeb S, Schölmerich J, Rogler G. 2007. Wound healing and fibrosis in intestinal disease. Gut 56:130–139.
5. Nadeem MS, Kumar V, Al-Abbasi FA, Kamal MA, Anwar F. 2019. Risk of colorectal cancer in inflammatory bowel diseases. Semin Cancer Biol 64:51–60.

6. Lopez LR, Bleich RM, Arthur JC. 2021. Microbiota effects on carcinogenesis: Initiation, promotion and progression. *Annu Rev Med* 72:1–19.
7. Schirmer M, Garner A, Vlamakis H, Xavier RJ. 2019. Microbial genes and pathways in inflammatory bowel disease. *Nat Rev Microbiol* 17:497–511.
8. Sartor RB. 2006. Mechanisms of disease: Pathogenesis of Crohn’s disease and ulcerative colitis. *Nat Clin Pract Gastroenterol Hepatol* 3:390–407.
9. Goethel A, Croitoru K, Philpott DJ. 2018. The interplay between microbes and the immune response in inflammatory bowel disease. *J Physiol* 596:3869–3882.
10. Caruso R, Lo BC, Núñez G. 2020. Host–microbiota interactions in inflammatory bowel disease. *Nat Rev Immunol* 20:411–426.
11. Sartor RB. 2008. Microbial influences in inflammatory bowel diseases. *Gastroenterology* 134:577–594.
12. Bäumlér AJ, Sperandio V. 2016. Interactions between the microbiota and pathogenic bacteria in the gut. *Nature* 535:85–93.
13. Hughes ER, Winter MG, Duerkop BA, Spiga L, Furtado de Carvalho T, Zhu W, Gillis CC, Buttner L, Smoot MP, Behrendt CL, Cherry S, Santos RL, Hooper L V., Winter SE. 2017. Microbial respiration and formate oxidation as metabolic signatures of inflammation-associated dysbiosis. *Cell Host Microbe* 21:208–219.
14. Dogan B, Suzuki H, Herlekar D, Sartor BRB, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP, Lefébure T, Chandler B, Schukken YH, Stanhope MJ, Simpson KW. 2014. Inflammation-associated adherent-invasive escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation. *Inflamm Bowel Dis* 20:1919–1932.

15. Mirsepasi-Lauridsen HC, Vallance BA, Krogfelt KA, Petersen AM. 2019. *Escherichia coli* pathobionts associated with inflammatory bowel disease. *Clin Microbiol Rev* 32:1–16.
16. Tenaillon O, Skurnik D, Picard B, Denamur E. 2010. The population genetics of commensal *Escherichia coli*. *Nat Rev Microbiol* 8:207–217.
17. Ellermann M, Gharaibeh RZ, Fulbright L, Dogan B, Moore LN, Broberg CA, Lopez LR, Rothemich AM, Herzog JW, Rogala A, Gordon IO, Rieder F, Brouwer CR, Simpson KW, Jobin C, Sartor RB, Arthur JC. 2019. Yersiniabactin-producing adherent/invasive *Escherichia coli* promotes inflammation-associated fibrosis in gnotobiotic IL-10^{-/-} mice. *Infect Immun* 87:1–18.
18. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan T-J, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C. 2012. Intestinal inflammation targets cancer-inducing activity of the microbiota. *Science* 338:120–123.
19. Martinez-Medina M, Garcia-Gil LJ. 2014. *Escherichia coli* in chronic inflammatory bowel diseases: An update on adherent invasive *Escherichia coli* pathogenicity . *World J Gastrointest Pathophysiol* 5:213-227.
20. Small CLN, Reid-Yu SA, McPhee JB, Coombes BK. 2013. Persistent infection with Crohn’s disease-associated adherent-invasive *Escherichia coli* leads to chronic inflammation and intestinal fibrosis. *Nat Commun* 4:1–12.
21. Carvalho FA, Barnich N, Sauvanet P, Darcha C, Gelot A, Darfeuille-Michaud A. 2008. Crohn’s disease-associated *Escherichia coli* LF82 aggravates colitis in injured mouse colon via signaling by flagellin. *Inflamm Bowel Dis* 14:1051–1060.

22. Carvalho FA, Koren O, Goodrich JK, Johansson MEV, Nalbantoglu I, Aitken JD, Su Y, Chassaing B, Walters WA, González A, Clemente JC, Cullender TC, Barnich N, Darfeuille-Michaud A, Vijay-Kumar M, Knight R, Ley RE, Gewirtz AT. 2012. Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. *Cell Host Microbe* 12:139–152.
23. Martinez-Medina M, Denizot J, Dreux N, Robin F, Billard E, Bonnet R, Darfeuille-Michaud A, Barnich N. 2014. Western diet induces dysbiosis with increased *E. coli* in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. *Gut* 63:116–124.
24. Dejea CM, Fathi P, Craig JM, Boleij A, Taddese R, Geis AL, Wu X, DeStefano Shields CE, Hechenbleikner EM, Huso DL, Anders RA, Giardiello FM, Wick EC, Wang H, Wu S, Pardoll DM, Housseau F, Sears CL. 2018. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. *Science* 359:592–597.
25. Nash JHE, Villegas A, Kropinski AM, Aguilar-Valenzuela R, Konczy P, Mascarenhas M, Ziebell K, Torres AG, Karmali MA, Coombes BK. 2010. Genome sequence of adherent-invasive *Escherichia coli* and comparative genomic analysis with other *E. coli* pathotypes. *BMC Genomics* 11:1–15.
26. Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. 2004. High prevalence of adherent-invasive *Escherichia coli* associated with ileal mucosa in Crohn's disease. *Gastroenterology* 127:412–421.
27. Ellermann M, Gharaibeh RZ, Maharshak N, Pérez-Chanona E, Jobin C, Carroll IM, Arthur JC, Plevy SE, Fodor AA, Brouwer CR, Sartor RB. 2020. Dietary iron variably

modulates assembly of the intestinal microbiota in colitis-resistant and colitis-susceptible mice. *Gut Microbes* 11:32–50.

28. Ellermann M, Huh EY, Liu B, Carroll IM, Tamayo R, Sartor RB. 2015. Adherent-invasive *Escherichia coli* production of cellulose influences iron-induced bacterial aggregation, phagocytosis, and induction of colitis. *Infect Immun* 83:4068–4080.
29. Delmas J, Gibold L, Faïs T, Batista S, Leremboure M, Sinel C, Vazeille E, Cattoir V, Buisson A, Barnich N, Dalmaso G, Bonnet R. 2019. Metabolic adaptation of adherent-invasive *Escherichia coli* to exposure to bile salts. *Sci Rep* 9:1–13.
30. Ormsby MJ, Johnson SA, Carpena N, Meikle LM, Goldstone RJ, McIntosh A, Wessel HM, Hulme HE, McConnachie CC, Connolly JPR, Roe AJ, Hasson C, Boyd J, Fitzgerald E, Gerasimidis K, Morrison D, Hold GL, Hansen R, Walker D, Smith DGE, Wall DM. 2020. Propionic acid promotes the virulent phenotype of Crohn’s disease-associated adherent-invasive *Escherichia coli*. *Cell Rep* 30:2297–2305.
31. Gogokhia L, Buhrke K, Bell R, Hoffman B, Brown DG, Hanke-Gogokhia C, Ajami NJ, Wong MC, Ghazaryan A, Valentine JF, Porter N, Martens E, O’Connell R, Jacob V, Scherl E, Crawford C, Stephens WZ, Casjens SR, Longman RS, Round JL. 2019. Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. *Cell Host Microbe* 25:285–299.
32. Schmitz JM, Tonkonogy SL, Dogan B, Leblond A, Whitehead KJ, Kim SC, Simpson KW, Sartor RB. 2019. Murine adherent and invasive *E. coli* induces chronic inflammation and immune responses in the small and large intestines of monoassociated IL-10^{-/-} mice independent of long polar fimbriae adhesin A. *Inflamm Bowel Dis* 25:875–885.
33. Tchaptchet S, Fan TJ, Goesser L, Schoenborn A, Gulati AS, Sartor RB, Hansen JJ. 2013.

Inflammation-induced acid tolerance genes gadAB in luminal commensal *Escherichia coli* attenuate experimental colitis. *Infect Immun* 81:3662–3671.

34. Kim SC, Tonkonogy SL, Albright CA, Tsang J, Balish EJ, Braun J, Huycke MM, Sartor RB. 2005. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. *Gastroenterology* 128:891–906.
35. Arthur JC, Gharaibeh RZ, Mühlbauer M, Perez-Chanona E, Uronis JM, McCafferty J, Fodor AA, Jobin C. 2014. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. *Nat Commun* 5:1–11.
36. Patwa LG, Fan TJ, Tchaptchet S, Liu Y, Lussier YA, Sartor RB, Hansen JJ. 2011. Chronic intestinal inflammation induces stress-response genes in commensal *Escherichia coli*. *Gastroenterology* 141:1842–1851.
37. Perry RD, Fetherston JD. 2011. Yersiniabactin iron uptake: mechanisms and role in *Yersinia pestis* pathogenesis. *Microbes Infect* 13:808–817.
38. Tronnet S, Garcie C, Rehm N, Dobrindt U, Oswald E, Martin P. 2016. Iron homeostasis regulates the genotoxicity of *Escherichia coli* that produces colibactin. *Infect Immun* 84:3358–3368.
39. Sharon G, Garg N, Debelius J, Knight R, Dorrestein PC, Mazmanian SK. 2014. Specialized metabolites from the microbiome in health and disease. *Cell Metab* 20:719–730.
40. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW. 2007. Culture independent analysis of ileal mucosa reveals a selective increase in invasive *Escherichia coli* of novel phylogeny relative to depletion of Clostridiales in Crohn's

disease involving the ileum. ISME J 1:403–418.

41. Bouvet O, Bourdelier E, Glodt J, Clermont O, Denamur E. 2017. Diversity of the auxotrophic requirements in natural isolates of *Escherichia coli*. Microbiology 163:891–899.
42. Li Z, Bouckaert J, Deboeck F, de Greve H, Hernalsteens JP. 2012. Nicotinamide dependence of uropathogenic *Escherichia coli* UTI89 and application of *nadB* as a neutral insertion site. Microbiology 158:736–745.
43. Di Martino ML, Fioravanti R, Barbabella G, Prosseda G, Colonna B, Casalino M. 2013. Molecular evolution of the nicotinic acid requirement within the *Shigella*/EIEC pathotype. Int J Med Microbiol 303:651–661.
44. Prunier AL, Schuch R, Fernández RE, Maurelli AT. 2007. Genetic structure of the *nadA* and *nadB* antivirulence loci in *Shigella* spp. J Bacteriol 189:6482–6486.
45. Ahmed ZU, Sarker MR, Sack DA. 1988. Nutritional requirements of *Shigellae* for growth in a minimal medium. Infect Immun 56:1007–1009.
46. Agus A, Planchais J, Sokol H. 2018. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe 23:716–724.
47. Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM. 2004. Enhanced *Escherichia coli* adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 127:80–93.
48. Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, Gambiez L, Joly B, Cortot A, Colombel JF. 1998. Presence of adherent *Escherichia coli* strains in ileal mucosa of patients with Crohn's disease. Gastroenterology 115:1405–1413.
49. Liu G, Foster J, Manlapaz-Ramos P, Olivera BM. 1982. Nucleoside salvage pathway for

- NAD biosynthesis in *Salmonella typhimurium*. *J Bacteriol* 152:1111–1116.
50. Bergthorsson U, Roth JR. 2005. Natural isolates of *Salmonella enterica* serovar Dublin carry a single *nadA* missense mutation. *J Bacteriol* 187:400–403.
51. Elhenawy W, Tsai CN, Coombes BK. 2019. Host-specific adaptive diversification of Crohn's disease-associated adherent-invasive *Escherichia coli*. *Cell Host Microbe* 25:301-312.
52. Kittana H, Gomes-Neto JC, Heck K, Sughrue J, Xian Y, Mantz S, Segura Muñoz RR, Cody LA, Schmaltz RJ, Anderson CL, Moxley RA, Hostetter JM, Fernando SC, Clarke J, Kachman SD, Cressler CE, Benson AK, Walter J, Ramer-Tait AE. 2019. Establishing the phenotypic basis of adherent-invasive *Escherichia coli* (AIEC) pathogenicity in intestinal inflammation. *bioRxiv* <https://doi.org/10.1101/772012>.
53. Nayfach S, Shi ZJ, Seshadri R, Pollard KS, Kyrpides NC. 2019. New insights from uncultivated genomes of the global human gut microbiome. *Nature* 568:505–510.
54. Moran NA. 2002. Microbial minimalism: Genome reduction in bacterial pathogens. *Cell* 108:583–586.
55. Prunier AL, Schuch R, Fernández RE, Kohler H, McCormick BA, Maurelli AT. 2007. *nadA* and *nadB* of *Shigella flexneri* 5a are antivirulence loci responsible for the synthesis of quinolinate, a small molecule inhibitor of *Shigella* pathogenicity. *Microbiology* 153:2363–2372.
56. Edwards RL, Bryan A, Jules M, Harada K, Buchrieser C, Swanson MS. 2013. Nicotinic acid modulates *Legionella pneumophila* gene expression and induces virulence traits. *Infect Immun* 81:945–955.
57. Cannizzo ES, Clement CC, Sahu R, Follo C. 2011. Oxidative stress, inflam-aging and

immunosenescence. J Proteomics 74:2313–2323.

58. Domergue R, Castano I, De Las Penas A, Zupancic M, Lockatell V, Hebel JR, Johnson D, Cormack BP. 2005. Nicotinic acid limitation regulates silencing of *Candida* adhesins during UTI. Science 308:866–870.
59. Utsumi R, Katayama S, Taniguchi M, Horie T, Ikeda M, Igaki S, Nakagawa H, Miwa A, Tanabe H, Noda M. 1994. Newly identified genes involved in the signal transduction of *Escherichia coli* K-12. Gene 140:73–77.
60. Hood MI, Skaar EP. 2012. Nutritional immunity: Transition metals at the pathogen-host interface. Nat Rev Microbiol 10:525–537.
61. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. Proc Natl Acad Sci U S A 97:6640–6645.
62. Sambrook J, Russell DW. 2006. The condensed protocols from molecular cloning : a laboratory manual.718.
63. Li H. 2016. Minimap and miniasm: Fast mapping and de novo assembly for noisy long sequences. Bioinformatics 32:2103–2110.
64. Vaser R, Sović I, Nagarajan N, Šikić M. 2017. Fast and accurate de novo genome assembly from long uncorrected reads. Genome Res 27:737–746.
65. Wang JR, Holt J, McMillan L, Jones CD. 2018. FMLRC: Hybrid long read error correction using an FM-index. BMC Bioinformatics 19:1–11.

Figure legends

Fig. 1. Nicotinic acid restores growth of *E. coli* NC101 in minimal media. (A) Wild-type NC101 was grown in Luria-Bertani (LB) broth, minimal media (MM), or MM + vitamin mix

(VM). Growth was measured at 8hr and 24hr by culture optical density, OD₆₀₀. (B) NC101 was grown in LB, MM, MM + VM, or MM supplemented with individual or combinations of vitamins and tryptophan. OD₆₀₀ was assessed at 8hr and 24hr. (C) Growth curve of NC101 in LB, MM, or MM + NA. (A, B) Bars (n = 3) or (C) points (n = 4) depict mean +/- SEM. Significance (*) is shown compared to NC101 growth in MM at (A,B) each timepoint or (C) 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 2. NA auxotrophy is not common among non-toxigenic *E. coli* strains, including prototypic AIEC LF82. (A) AIEC and non-AIEC *E. coli* isolates, were grown in minimal media (MM) with and without nicotinic acid (NA). Growth was evaluated at 2hr, 4hr, 8hr, and 24hr by OD₆₀₀. (B) Growth curve of wild-type NC101 and LF82 (human-derived AIEC) in MM with and without NA. (A) Bars (n = 3-6) or (B) points (n = 3) depict mean +/- SEM. (A) Strains grown in MM were compared to NC101 grown in MM, and strains grown in MM + NA were compared to NC101 grown in MM + NA. Significance (*) is shown compared at (A) each timepoint or (B) 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 3. NC101 has a defect in the *de novo* NAD biosynthesis pathway. (A) Illustration of NAD biosynthesis pathway in *E. coli*, including pathway intermediates and genes involved. Intermediates tested in *E. coli* growth assays are indicated by stars (blue restored growth, white did not). Bolded genes, *nadA* and *nadB*, are predicted to be responsible for NC101 auxotrophy. (B) Wild-type NC101 was grown in minimal media (MM), MM + vitamin mix (VM), or MM +

NAD biosynthesis pathway intermediates: L-aspartate (L-Asp), quinolinic acid (Qa), nicotinamide (Nm), nicotinic acid (NA), and NAD. Culture density was evaluated at 2hr, 4hr, 8hr, or 24hr by OD₆₀₀. (C) Growth curve of NC101 in MM with or without Qa, Nm, NA, or NAD. (B) Bars (n = 3-6) or (C) points (n = 3) depict mean +/- SEM. Significance (*) is shown compared to NC101 growth in MM at (B) each timepoint or (C) 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 4. A missense mutation in NAD biosynthesis gene *nadA* confers NA auxotrophy in NC101. (A) Genetic alignment of partial *nadA* sequence from NA auxotrophic (Wild-type (WT) NC101) and prototrophic (NC101 NA_D, LF82, and K12) *E. coli*. Nucleotide and amino acid sequences, noted by 1 letter abbreviations, are shown. The ruler displays nucleotide position of coding sequence. The identity bar displays regions of similarity (black) or dissimilarity (grey or blue). The highlighted amino acids show the region of noted dissimilarity (*nadA* G263T) between NA auxotrophic (grey) and prototrophic (blue) *E. coli*. (B) A growth curve of WT NC101 and prototrophic revertant NC101 strain (NA_D) in minimal media (MM) with and without nicotinic acid (NA). Growth was measured by culture optical density, OD₆₀₀. Points depict mean +/- SEM (n = 4). Significance (*) is shown compared to NC101 growth in MM at 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 5. Correcting NA auxotrophy in NC101 has minimal impact on *in vitro* AIEC function. (A) Wild-type (WT) NC101, prototrophic NC101 NA_D, and non-motile control NC101 Δ *fliC*

were grown on minimal media (MM) soft agar plates with nicotinic acid (NA). Diameter of motility swarm spots (mm) were measured at 8hr (n = 3-5). **(B-D)** J774A.1 murine macrophages were infected at a multiplicity of infection (MOI) = 10 with WT or NA_D. Bacterial culture media before infection (“Bacteria”) or cell culture media during infection (“Macrophage”) were with or without NA supplementation. Number of bacteria are shown at **(B)** 1hr or **(C)** 24hr post-infection as Log₁₀ colony forming units (CFU)/mL. **(D)** Percent survival = [(CFU/mL at 24hr)/(CFU/mL at 1hr)]×100 (n = 3-4). Bars depict mean +/- SEM. Significance (*) is shown compared to WT NC101 and was determined at p < 0.05, using a **(A)** one-way ANOVA with Dunnett’s T3 multiple comparisons test or **(B-D)** Welch’s t test.

Figures

Fig. 1. Nicotinic acid restores growth of *E. coli* NC101 in minimal media. (A) Wild-type NC101 was grown in Luria-Bertani (LB) broth, minimal media (MM), or MM + vitamin mix (VM). Growth was measured at 8hr and 24hr by culture optical density, OD₆₀₀. (B) NC101 was grown in LB, MM, MM + VM, or MM supplemented with individual or combinations of vitamins and tryptophan. OD₆₀₀ was assessed at 8hr and 24hr. (C) Growth curve of NC101 in LB, MM, or MM + NA. (A, B) Bars (n = 3) or (C) points (n = 4) depict mean +/- SEM. Significance (*) is shown compared to NC101 growth in MM at (A,B) each timepoint or (C) 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 2. NA auxotrophy is not common among non-toxi-genic *E. coli* strains, including prototypic AIEC LF82.

(A) AIEC and non-AIEC *E. coli* isolates, were grown in minimal media (MM) with and without nicotinic acid (NA). Growth was evaluated at 2hr, 4hr, 8hr, and 24hr by OD₆₀₀. (B) Growth curve of wild-type NC101 and LF82 (human-derived AIEC) in MM with and without NA. (A) Bars (n = 3-6) or (B) points (n = 3) depict mean $\pm$ SEM. (A) Strains grown in MM were compared to NC101 grown in MM, and strains grown in MM + NA were compared to NC101 grown in MM + NA. Significance (*) is shown compared at (A) each timepoint or (B) 24hr and was determined at $p < 0.05$, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 3. NC101 has a defect in the de novo NAD biosynthesis pathway. (A) Illustration of NAD biosynthesis pathway in *E. coli*, including pathway intermediates and genes involved. Intermediates tested in *E. coli* growth assays are indicated by stars (blue restored growth, white did not). Bolded genes, *nadA* and *nadB*, are predicted to be responsible for NC101 auxotrophy. (B) Wild-type NC101 was grown in minimal media (MM), MM + vitamin mix (VM), or MM + NAD biosynthesis pathway intermediates: L-aspartate (L-Asp), quinolinic acid (Qa), nicotinamide (Nm), nicotinic acid (NA), and NAD. Culture density was evaluated at 2hr, 4hr, 8hr, or 24hr by OD₆₀₀. (C) Growth curve of NC101 in MM with or without Qa, Nm, NA, or NAD. (B) Bars (n = 3-6) or (C) points (n = 3) depict mean $\pm$ SEM. Significance (*) is shown compared to NC101 growth in MM at (B) each timepoint or (C) 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 4. A missense mutation in NAD biosynthesis gene *nadA* confers NA auxotrophy in NC101. (A) Genetic alignment of partial *nadA* sequence from NA auxotrophic (Wild-type (WT) NC101) and prototrophic (NC101 NA_D, LF82, and K12) *E. coli*. Nucleotide and amino acid sequences, noted by 1 letter abbreviations, are shown. The ruler displays nucleotide position of coding sequence. The identity bar displays regions of similarity (black) or dissimilarity (grey or blue). The highlighted amino acids show the region of noted dissimilarity (*nadA* G263T) between NA auxotrophic (grey) and prototrophic (blue) *E. coli*. (B) A growth curve of WT NC101 and prototrophic revertant NC101 strain (NA_D) in minimal media (MM) with and without nicotinic acid (NA). Growth was measured by culture optical density, OD₆₀₀. Points depict mean $\pm$ SEM (n = 4). Significance (*) is shown compared to NC101 growth in MM at 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

649

Fig. 5. Correcting NA auxotrophy in NC101 has minimal impact on in vitro AIEC function. (A) Wild-type (WT) NC101, prototrophic NC101 NA_D, and non-motile control NC101 ΔfliC were grown on minimal media (MM) soft agar plates with nicotinic acid (NA). Diameter of motility swarm spots (mm) were measured at 8hr (n = 3-5). (B-D) J774A.1 murine macrophages were infected at a multiplicity of infection (MOI) = 10 with WT or NA_D. Bacterial culture media before infection ("Bacteria") or cell culture media during infection ("Macrophage") were with or without NA supplementation. Number of bacteria are shown at (B) 1hr or (C) 24hr post-infection as Log₁₀ colony forming units (CFU)/mL. (D) Percent survival = [(CFU/mL at 24hr)/(CFU/mL at 1hr)×100 (n = 3-4). Bars depict mean ± SEM. Significance (*) is shown compared to WT NC101 and was determined at p < 0.05, using a (A) one-way ANOVA with Dunnett's T3 multiple comparisons test or (B-D) Welch's t test.

658 **Tables**

Table 1

Escherichia coli strains used in this study.

Strain	Description of non-virulent <i>E. coli</i> strains	Isolated from:	Adherent- invasive <i>E. coli</i> (AIEC) Status	Reference or Source
Wild-type (WT) NC101	Streptomycin resistant (Str ^R) isolate of classical murine- derived AIEC	Laboratory <i>E. coli</i> isolate	AIEC	(34), This study
LF82	Classical human-adapted clinical AIEC isolate	Crohn's disease patient	AIEC	(48)
42ET-1	Clinical AIEC isolate	Non-IBD ^a patient	AIEC	(40)
568-3	Clinical AIEC isolate	Crohn's disease patient	AIEC	(40)
K12 (MG1655)	Model <i>E. coli</i> strain	Laboratory <i>E. coli</i> isolate	Non-AIEC	ATCC [®] 700926 TM
25922	Model <i>E. coli</i> strain	Patient	Non-AIEC	ATCC [®] 25922 TM

HM670	Clinical <i>E. coli</i> isolate	Crohn's disease patient	Non-AIEC, but has enhanced survival in macrophages	(47)
37RT-2	Clinical <i>E. coli</i> isolate	Non-IBD ^a patient	Non-AIEC	(40)
532-9	Clinical <i>E. coli</i> isolate	Crohn's disease patient	Non-AIEC	(40)
39ES-1	Clinical <i>E. coli</i> isolate	Crohn's disease patient	Non-AIEC	(40)
Nicotinic acid revertant (NA _{derivative} or NA _D) NC101	Spontaneous prototrophic revertant of WT NC101 (G263T mutation in <i>nadA</i>)	Laboratory <i>E. coli</i> isolate	N.D. ^b , but exhibits survival in macrophages	This study
NC101 Δ <i>fliC</i>	Non-motile flagellin mutant derived from WT NC101	Laboratory <i>E. coli</i> isolate	N.D. ^b	This study

^aIBD = inflammatory bowel disease, ^bN.D. = not determined

659

660

Table 2

Repository information for published genomic sequences.

Accession	Sample Name	Strain	Organism	Tax ID	BioProject	Used in this study?	URL
SAMN16810910	JA0058	Original NC101 strain	<i>E. coli</i>	562	PRJNA678715	No	https://www.ncbi.nlm.nih.gov/biosample/SAMN16810910/
SAMN16810911	JA0072	Streptomycin resistant (Str ^R) isolate of original NC101	<i>E. coli</i>	562	PRJNA678715	Yes	https://www.ncbi.nlm.nih.gov/biosample/?term=SAMN16810911
SAMN16810912	JA0257	Spontaneous prototrophic revertant of Str ^R NC101 (G263T mutation in <i>nadA</i>)	<i>E. coli</i>	562	PRJNA678715	Yes	https://www.ncbi.nlm.nih.gov/biosample/?term=SAMN16810912

SAMN16	JA0265	Spontaneous	<i>E. coli</i>	562	PRJNA678	No	https://www.n
810913		prototrophic			715		cbi.nlm.nih.go
		revertant of					v/biosample/?
		original					term=SAMN1
		NC101					6810913
		(G263T					
		mutation in					
		<i>nadA</i>)					
SAMN16	JA0266	Spontaneous	<i>E. coli</i>	562	PRJNA678	No	https://www.n
810914		prototrophic			715		cbi.nlm.nih.go
		revertant of					v/biosample/?
		original					term=SAMN1
		NC101					6810914
		(T1014G					
		mutation in					
		<i>nadA</i>)					

661

Table 3

Primers used for strain construction.

Primer	Sequence (5'-3')	Reference
Knockout_ <i>fliC</i>	GGAAACCCAAAACGTAATCAACGACTTGCAATATAG	This study
forward	GATAACGAA TCATGATT CCGGGGATCCG TCGACC	

Knockout_ <i>fliC</i>	GTCAGTCTCAGTTAATCAGGTTACGACGATTAACCC	This study
reverse	TGCAGCAGAGACAGTGTAGGCTGGAGCTGCTTCG	
<i>fliC</i> upstream	GACGATAACAGGGTTGACGG	This study
<i>fliC</i> downstream	ATTGCAATTCCCCTTGTAGG	This study

Fig. 1. Nicotinic acid restores growth of *E. coli* NC101 in minimal media. (A) Wild-type NC101 was grown in Luria-Bertani (LB) broth, minimal media (MM), or MM + vitamin mix (VM). Growth was measured at 8hr and 24hr by culture optical density, OD₆₀₀. (B) NC101 was grown in LB, MM, MM + VM, or MM supplemented with individual or combinations of vitamins and tryptophan. OD₆₀₀ was assessed at 8hr and 24hr. (C) Growth curve of NC101 in LB, MM, or MM + NA. (A, B) Bars (n = 3) or (C) points (n = 4) depict mean +/- SEM. Significance (*) is shown compared to NC101 growth in MM at (A,B) each timepoint or (C) 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 3. NC101 has a defect in the de novo NAD biosynthesis pathway. (A) Illustration of NAD biosynthesis pathway in *E. coli*, including pathway intermediates and genes involved. Intermediates tested in *E. coli* growth assays are indicated by stars (blue restored growth, white did not). Bolded genes, *nadA* and *nadB*, are predicted to be responsible for NC101 auxotrophy. (B) Wild-type NC101 was grown in minimal media (MM), MM + vitamin mix (VM), or MM + NAD biosynthesis pathway intermediates: L-aspartate (L-Asp), quinolinic acid (Qa), nicotinamide (Nm), nicotinic acid (NA), and NAD. Culture density was evaluated at 2hr, 4hr, 8hr, or 24hr by OD₆₀₀. (C) Growth curve of NC101 in MM with or without Qa, Nm, NA, or NAD. (B) Bars (n = 3-6) or (C) points (n = 3) depict mean $\pm$ SEM. Significance (*) is shown compared to NC101 growth in MM at (B) each timepoint or (C) 24hr and was determined at $p < 0.05$, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 4. A missense mutation in NAD biosynthesis gene *nadA* confers NA auxotrophy in NC101. (A) Genetic alignment of partial *nadA* sequence from NA auxotrophic (Wild-type (WT) NC101) and prototrophic (NC101 NAD, LF82, and K12) *E. coli*. Nucleotide and amino acid sequences, noted by 1 letter abbreviations, are shown. The ruler displays nucleotide position of coding sequence. The identity bar displays regions of similarity (black) or dissimilarity (grey or blue). The highlighted amino acids show the region of noted dissimilarity (*nadA* G263T) between NA auxotrophic (grey) and prototrophic (blue) *E. coli*. (B) A growth curve of WT NC101 and prototrophic revertant NC101 strain (NA_D) in minimal media (MM) with and without nicotinic acid (NA). Growth was measured by culture optical density, OD₆₀₀. Points depict mean +/- SEM (n = 4). Significance (*) is shown compared to NC101 growth in MM at 24hr and was determined at p < 0.05, using a one-way ANOVA with Dunnett's T3 multiple comparisons test.

Fig. 5. Correcting NA auxotrophy in NC101 has minimal impact on in vitro AIEC function. (A) Wild-type (WT) NC101, prototrophic NC101 NA_D, and non-motile control NC101 $\Delta fliC$ were grown on minimal media (MM) soft agar plates with nicotinic acid (NA). Diameter of motility swarm spots (mm) were measured at 8hr (n = 3-5). (B-D) J774A.1 murine macrophages were infected at a multiplicity of infection (MOI) = 10 with WT or NA_D. Bacterial culture media before infection ("Bacteria") or cell culture media during infection ("Macrophage") were with or without NA supplementation. Number of bacteria are shown at (B) 1hr or (C) 24hr post-infection as Log₁₀ colony forming units (CFU)/mL. (D) Percent survival = [(CFU/mL at 24hr)/(CFU/mL at 1hr) × 100 (n = 3-4). Bars depict mean +/- SEM. Significance (*) is shown compared to WT NC101 and was determined at p < 0.05, using a (A) one-way ANOVA with Dunnett's T3 multiple comparisons test or (B-D) Welch's t test.